Akamis Bio

An infusion bag, and a very specific virus

Somewhere in a clinical trial ward, a nurse hangs an IV bag. Inside it: not a syringe aimed at a tumor, not a pill swallowed and dispersed, but a virus - engineered, counted, dosed - that will travel the bloodstream looking for one thing only. Akamis Bio builds therapies you give the way you'd give an antibiotic, and which behave the way a guided package would. The cancer is the address. The virus does the delivery.

This is a clinical-stage oncology company of roughly 36 people, headquartered at 245 Main Street in Cambridge, Massachusetts. It is small. Its ambition is not. Akamis wants to do the thing oncology has wanted for decades: hit solid tumors everywhere they hide - primary site, metastases, the spots a needle could never reach - without poisoning everything else along the way.

Solid tumors are good at hiding

Immunotherapy has been the great story of modern oncology. Checkpoint inhibitors, CAR-T cells, bispecific antibodies - real progress, real survivors. But solid tumors, the epithelial-derived cancers that make up most of the diagnoses, have a frustrating habit of staying cold. They build stromal walls. They switch off immune signals. They sit in places a clinician cannot easily inject.

The obvious fix - flood the bloodstream with a powerful immune agonist - has an obvious cost. A drug like a CD40 agonist can rally the immune system beautifully and, given systemically at the doses you'd need, can also make the patient very sick. The dose that works and the dose that's tolerable rarely shake hands.

So the question Akamis set out to answer was narrow and stubborn: how do you deliver a potent immune signal to a tumor - including tumors scattered through the body - at concentrations high enough to matter, without dosing the entire patient at the same level?

A British science story, relocated

Akamis Bio did not appear from nothing. It was founded in 2010 as PsiOxus Therapeutics by John Beadle, Kerry Fisher, and Andrew Coats, with Fisher - an Oxford gene-therapy scientist - as the intellectual engine and Chief Scientific Officer. Their bet was that a virus could be turned into a programmable delivery vehicle for cancer, not just a blunt instrument that lyses cells.

The bet had a twist most oncolytic-virus companies didn't make. Rather than design the perfect vector on paper, they used directed evolution - the let-biology-do-the-optimizing approach that's earned Nobel recognition elsewhere - to breed an adenovirus that selectively infects epithelial tumor tissue. You don't argue the virus into specificity. You select for it.

In 2022 the company rebranded to Akamis Bio, took $30 million from US investors including ARCH Venture Partners, Westlake Village BioPartners, and the Parker Institute, and pulled its center of gravity across the Atlantic to Cambridge, Massachusetts. Howard Davis, PhD, took the CEO seat. The British science kept its passport but moved house.

T-SIGn: the tumor as a drug factory

The platform is called T-SIGn - Tumor-Specific Immuno-Gene therapy. The mechanics are elegant enough to explain at a dinner party, which in biotech is rare. You infuse a replication-competent, chimeric group B adenovirus. It circulates. Thanks to that directed-evolution pedigree, it selectively enters epithelial-derived solid tumor cells and largely ignores healthy tissue. Once inside, it does two things at once: it replicates and attacks the tumor directly, and it forces the tumor cell to express transgene payloads - immune-modulating drugs manufactured right there, in the tumor.

The tumor becomes, in the company's own framing, a drug factory. The factory runs hot exactly where you want it and stays quiet everywhere else.

The lead program, NG-350A, is the cleanest demonstration of the idea. Given intravenously, it drives the tumor to express a CD40 agonist monoclonal antibody - that same potent immune signal that's so hard to give safely on its own - in both primary and metastatic tumors. As CEO Howard Davis puts it, the point is concentration where it counts.

Because it travels through the blood rather than a needle, T-SIGn can reach the tumors a clinician can't physically inject - the deep ones, the spread-out ones, the metastatic ones. And because the vector can carry multiple transgenes, the same platform can express cytokines, chemokines, or antibodies in combination. One delivery system, many possible payloads. The platform, not any single drug, is the real asset.

Numbers, partners, and patients

A clever mechanism is a hypothesis until people get dosed. Akamis has dosed a lot of them - more than 240 patients across its clinical studies to date, with what the company reports as a consistent safety profile in its Phase 1a work. NG-350A has moved into Phase 1b combinations, including with pembrolizumab, and into a separate pancreatic-cancer study run with the Parker Institute and Cancer Research Institute.

The money tells a story too. The December 2024 financing - $60 million linked to a Series A Prime led by Sedgwick Yard, a biotech VC with Greater China roots - arrived alongside a licensing deal handing Xuanzhu Biopharma the Greater China rights to NG-350A, complete with upfront payments, milestones, and tiered royalties back to Akamis. Two Sedgwick Yard managing directors, Richard Shen and Adrian Chan, joined the board. Capital and a commercial validation in the same press release is the kind of thing biotech boards like.

And then there are the names on the platform collaborations: Bristol Myers Squibb, Merck, and the Parker Institute for Cancer Immunotherapy. Large pharma doesn't sign T-SIGn collaborations for the brochure. It signs because the vector can carry their molecules to places their molecules can't go alone.

Smaller surgeries, bigger lives

For all the platform talk, Akamis frames its near-term mission in unusually human terms: transform the standard of care for people living with colorectal cancer. The FORTRESS trial in locally advanced rectal cancer is the sharp end of that. Rectal cancer treatment can mean life-altering surgery. A therapy that shrinks tumors enough to spare a patient that outcome is not an abstract endpoint - it's a different life.

The company describes a culture built on five plain principles: patient-centric commitment, entrepreneurial risk-taking, operational urgency, performance accountability, and investing in its people. It's the sort of values list every biotech publishes. What gives this one a little weight is the urgency line - a 36-person company chasing solid tumors does not have the luxury of moving slowly.

A platform that keeps its options

Here's the part skeptics should sit with. If T-SIGn works as a delivery system, NG-350A is the first of a series, not the whole story. Preclinical data already suggests the vectors can boost CAR-T cells - improving their trafficking and survival while lowering systemic toxicity. A platform that can express different payloads, in different cancers, in combination, is the kind of asset that compounds. One good vector becomes many shots on goal.

None of that is proven yet. Phase 1b is not Phase 3, proof of mechanism is not approval, and oncology is a graveyard of elegant mechanisms that didn't translate. The honest read on Akamis Bio is that it has a genuinely clever idea, real patients dosed, brand-name partners, fresh capital, and a long clinical road still ahead.

Back to that infusion bag. A nurse hangs it; the virus goes looking for its address. If Akamis is right, the most remarkable thing in that room won't be the technology - it'll be how ordinary the moment looks. No surgery scheduled, no needle threaded into a tumor, just a bag on a pole and a cancer quietly being told to manufacture the thing that helps undo it. That's the future Akamis Bio is trying to make boring. In oncology, boring is the highest compliment there is.